This drug researcher just reported earnings and could keep rallying on biotech bounceback, JPMorgan says
JPMorgan upgraded Charles River Laboratories (CRL) to overweight from neutral and raised its 12-month price target to $310 from $180, citing stronger momentum in its discovery and safety assessment business. Charles River reported 2Q EPS of $3.02 (ex items) vs $2.74 expected and revenue of about $1.0B vs $977.2M consensus, and lifted 2026 guidance to $11.15-$11.45.
How this was made
The 30-second read
Why it matters
The combination of an earnings/guidance beat and a sell-side upgrade with a materially higher price target can drive additional momentum trading and re-rate expectations for CRO peers tied to biotech funding.
Market read
Traders may treat this as a momentum catalyst for CRL tied to biotech funding read-through, with attention on whether bookings/proposals remain strong.
What to watch
Biotech funding and large pharma activity are cyclical; if deal flow slows, the DSA momentum thesis could weaken even with a guidance raise.
Background
Charles River Laboratories reported 2Q results and raised 2026 guidance, with JPMorgan framing the move as sustainable momentum in its Discovery and Safety Assessment (DSA) business.
Ticker impact
JPMorgan upgraded Charles River to overweight and raised its 12-month price target to $310 after the company beat EPS and raised 2026 guidance.
Bullish bias for follow-through trading, with volatility around any subsequent biotech-funding headlines.
The article cites specific 2Q results (EPS, revenue) and a raised 2026 earnings forecast, alongside a same-day JPMorgan target hike tied to sustainable DSA momentum.
Market effects
Supports the biotech services/contract research theme by reinforcing read-through from biotech funding and large pharma activity to CRO bookings.
Limited; Charles River is US-based and the catalyst is company-specific.
Moderate; biotech funding trends are global, but the immediate driver is CRL’s guidance and sell-side stance.
Counterpoint
The JPMorgan target implies substantial upside, so further gains may depend on continued bookings strength rather than already-repriced expectations.
Key entities
- companyCharles River Laboratories
CRO whose 2Q results and raised 2026 earnings forecast prompted a JPMorgan upgrade and higher price target.
- financial_institutionJPMorgan
Upgraded CRL to overweight and raised its 12-month price target to $310 from $180.
